Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 16/20 | 0.78 |
| ▸ | THRA | P10827 | 15/20 | 0.78 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328469 | 0.88 | THRA (1.00) | THRBTHRA | |
| SCHEMBL282541 | 0.86 | THRB (0.77) | THRBTHRA | |
| SCHEMBL328509 | 0.85 | THRB (0.59) | THRBTHRAPTPN1ADRB2ADRB3 | |
| SCHEMBL13044628 | 0.81 | THRB (0.76) | THRBTHRA | |
| SCHEMBL13381655 | 0.79 | THRB (0.65) | THRBTHRA | |
| SCHEMBL13381669 | 0.78 | THRB (0.53) | THRBTHRAADRB2ADRB3 | |
| SCHEMBL19982699 | 0.78 | THRB (0.67) | THRBTHRAPTPN1 | |
| SCHEMBL13381641 | 0.76 | THRA (0.80) | THRBTHRACETP | |
| SCHEMBL21291168 | 0.75 | THRA (0.78) | THRBTHRA | |
| SCHEMBL3160054 | 0.74 | THRB (0.71) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | TSHR, TPO, THRA | THRB 4/4885THRA 3/4885PTPN1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.